<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586608</url>
  </required_header>
  <id_info>
    <org_study_id>201802</org_study_id>
    <nct_id>NCT04586608</nct_id>
  </id_info>
  <brief_title>Investigation of Administration of MCT/ω-3 Fatty Acids is Towards Anti-inflammatory Related Fatty Acid Profile in Preterm Neonates.</brief_title>
  <acronym>MCT/ω-3 FA</acronym>
  <official_title>Administration of an Intravenous Fat Emulsion Enriched With MCT/ω-3 Fatty Acids is Beneficial Towards Anti-inflammatory Related Fatty Acid Profile in Preterm Neonates: a Randomized, Double-blind Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iaso Maternity Hospital, Athens, Greece</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iaso Maternity Hospital, Athens, Greece</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous administration of pure soybean oil emulsions high in linoleic acid may lead to&#xD;
      inflammation and lipid peroxidation in preterm neonates. The aim of the present study was to&#xD;
      investigate the effects of a medium-chain triglyceride (MCT)/n-3 polyunsaturated fatty acid&#xD;
      (PUFA)-enriched intravenous fat emulsion (IVFE) on plasma fatty acid (FA) profile in preterm&#xD;
      neonates. Methods: In this double-blind randomized study, 92 preterm neonates (gestational&#xD;
      age &lt;32 weeks, birth weight &lt;1500g) were assigned to receive either MCT/n-3 PUFA-enriched&#xD;
      IVFE (Intervention Group) or soybean oil-based IVFE (Control Group). Neonates' parents gave&#xD;
      their informed written consent for inclusion in the study. Levels of FAs were measured at&#xD;
      baseline (day 0) and day 15 of parenteral nutrition with gas-chromatography&#xD;
      mass-spectrometry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alterations on Metabolic Fatty Acid Profile of the Premature Neonates</measure>
    <time_frame>two years</time_frame>
    <description>the detection of clinically significant differences in plasma n-3 PUFAs, n-6 PUFAs and EPA in the MCT/ω-3 PUFA-enriched IVFE group compared to the SO-IVFE group post intervention.&#xD;
the detection of clinically significant differences in plasma n-3 PUFAs, n-6 PUFAs and EPA in the MCT/ω-3 PUFA-enriched IVFE group compared to the SO-IVFE group post intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>soybean oil-based IVFE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>soybean oil-based IVFE</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MCT/ω-3 fatty acids</intervention_name>
    <description>The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.</description>
    <arm_group_label>active comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soybean oil-based IVFE</intervention_name>
    <description>soybean oil-based IVFE</description>
    <arm_group_label>soybean oil-based IVFE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Preterm neonates with gestational age &lt;32 weeks&#xD;
&#xD;
          -  birth weight &lt;1500 g&#xD;
&#xD;
          -  admitted to a tertiary neonatal intensive care unit within 12 hours after birth&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  anticipated needs for parenteral nutrition (PN) at ˃70% of total daily energy for &lt;10&#xD;
             days evidence of intrauterine infection,&#xD;
&#xD;
          -  perinatal asphyxia&#xD;
&#xD;
          -  major congenital anomalies&#xD;
&#xD;
          -  refusal of parental consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Panos Papandreou</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iaso Maternity Hospital, Athens, Greece</investigator_affiliation>
    <investigator_full_name>Panos Papandreou</investigator_full_name>
    <investigator_title>pharmD PhDc Head of Parenteral Nutrition Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

